Miscellaneous Agents in Cancer Therapy
Start with the big picture
The lesson organizes these drugs by how they affect cancer cells or the tumor environment. Hydroxyurea, procarbazine, and asparaginase-related agents illustrate enzyme inhibition and nutrient depletion; mitotane and interferon-α represent adrenolytic and immune-modulating approaches. Targeted therapies include tyrosine kinase inhibitors acting on BCR-ABL, c-KIT, PDGFR, EGFR, VEGFR, or RAF pathways. The topic also introduces proteasome inhibitors, thalidomide-related immunomodulators, and monoclonal antibodies such as rituximab. Across these groups, the source connects selected indications with clinically important risks, including myelosuppression, organ-specific toxicities, and treatment-related complications. This preview highlights the overall structure; the full lesson develops the individual agents and their distinguishing features.
What you'll learn
- Describe the mechanisms and selected uses of hydroxyurea, procarbazine, and asparaginase-related agents.
- Distinguish adrenolytic and immune-modulating approaches represented by mitotane and interferon-α.
- Relate major tyrosine kinase inhibitor targets to the cancers identified in the lesson.
- Recognize key adverse effects associated with proteasome inhibitors and immunomodulatory drugs.
- Identify the role of monoclonal antibodies within the topic’s cancer therapy categories.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
